Resverlogix has expanded the Phase IIb clinical trial for analysing apabetalone (RVX-208) as a potential oral Covid-19 therapy to Brazil.
CALGARY, Alberta, March 23, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”) (RVX.TO) announces that it is seeking to collaborate with organizations currently testing therapies for SARS-CoV-2 (the virus responsible for COVID-19) in pre-clinical or clinical models. Apabetalone prevents specialized proteins – called bromodomain and extraterminal domain (BET) proteins – from activating the expression of disease-associated and other genes, potentially disrupting SARS-CoV-2 reproduction while also limiting the entry of the virus into human cells.